NCT04543955
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least one prior systemic cancer treatment for this diagnosis
Exclusions: Patients with prior exposure to Lutetium Lu 177 Dotatate
https://ClinicalTrials.gov/show/NCT04543955